Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain excitatory neurons (91 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 15647
Sealed predictions
- CREG2 in dopamine neurons, braak-0.48 (p 0.190) → +0.18 (p 0.639)receipt 15653
Swarm cases
receipt 15653: CREG2 in dopamine neurons, braak
- power
- full sample -0.13 (p 0.621, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.15 (p 0.549, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.429, n 18). could be the mix.
- skeptic
- leave-one-out range -0.24 to +0.01, sign flips 1; without severely affected donors -0.13 (p 0.621, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CREG2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts